Literature DB >> 11754595

Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model.

Muthusamy Jayaraman1, Brian M Fox, Melinda Hollingshead, Glenda Kohlhagen, Yves Pommier, Mark Cushman.   

Abstract

A number of novel dihydroindenoisoquinolines and indenoisoquinolinium salts were synthesized and examined for cytotoxicity in cancer cell cultures and for inhibition of topoisomerase I (top1). The top1-mediated DNA cleavage patterns produced in the presence of several of the new analogues were also investigated, and a few of the more potent compounds were examined for activity in hollow fiber animal models. Very cytotoxic dihydroindenoisoquinoline and isoquinolinium salts were obtained with mean graph midpoints (MGMs) for growth inhibition in the low submicromolar range. Two of the new dihydroindenoisoquinolines were found to be weaker top1 inhibitors than the lead compound 1, while two of the indenoisoquinolinium salts were more potent. The top1-mediated DNA cleavage patterns of the indenoisoquinolines examined were found to be similar to each other but different from that of camptothecin. Several of the more potent indenoisoquinolines displayed promising anticancer activities in hollow fiber animal models.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11754595     DOI: 10.1021/jm000498f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.

Authors:  Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

2.  Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.

Authors:  Andrew Morrell; Michael S Placzek; Jamin D Steffen; Smitha Antony; Keli Agama; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2007-04-03       Impact factor: 7.446

3.  A Facile method to transform trans-4-carboxy-3,4-dihydro-3-phenyl- 1(2H)-isoquinolones to indeno[1,2-c]isoquinolines.

Authors:  Xiangshu Xiao; Mark Cushman
Journal:  J Org Chem       Date:  2005-08-05       Impact factor: 4.354

4.  Application of sequential Cu(I)/Pd(0)-catalysis to solution-phase parallel synthesis of combinatorial libraries of dihydroindeno[1,2-c]isoquinolines.

Authors:  Sarvesh Kumar; Thomas O Painter; Benoy K Pal; Benjamin Neuenswander; Helena C Malinakova
Journal:  ACS Comb Sci       Date:  2011-07-20       Impact factor: 3.784

5.  Correlative effect between in vivo hollow fiber assay and xenografts assay in drug screening.

Authors:  Keyong Ho Lee; Ki Hyeong Rhee
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

6.  5-Phenyl-7,8-dihydro-1,3-dioxano[4,5-g]isoquinoline.

Authors:  Jiu-Ming Li; Dong Liang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-11-08

7.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

Authors:  Yves Pommier; Mark Cushman
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

Review 8.  DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.

Authors:  Yves Pommier
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

9.  (15)N{(31)P} REDOR NMR studies of the binding of phosphonate reaction intermediate analogues to Saccharomyces cerevisiae lumazine synthase.

Authors:  Tsyr-Yan Yu; Robert D O'Connor; Astrid C Sivertsen; Colby Chiauzzi; Barbara Poliks; Markus Fischer; Adelbert Bacher; Ilka Haase; Mark Cushman; Jacob Schaefer
Journal:  Biochemistry       Date:  2008-12-30       Impact factor: 3.162

Review 10.  Structural studies of type I topoisomerases.

Authors:  Nicole M Baker; Rakhi Rajan; Alfonso Mondragón
Journal:  Nucleic Acids Res       Date:  2008-12-23       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.